Pharmaceuticals
October 19, 2026
Daniel Szawarnoga, Joanna Fojcik, Michał Kamil Górski et al.
Treatment-resistant depression (TRD) remains one of the most clinically challenging forms of depressive disorders. In many patients, reduction in symptom severity does not translate into full functional recovery; therefore, assessment of treatment effectiveness should also include health-related quality of life (HRQoL). Objective: The aim of the study was to compare changes in HRQoL in patients...
Nature Neuroscience
October 19, 2026
Patricia Molina, Denys Osypenko, Josep Garnica et al.
Abstract Chronic stress has lasting adverse consequences that can lead, over time, to depressive disorders1‑4 yet identifying the optimal timeframe for effective therapies remains an unmet challenge. Enhanced neuronal activity and disrupted aversion-encoding in lateral habenula (LHb) are important mediators of stress-related behavioral repercussions5‑10, although the precise timing of its...
Therapeutics
October 19, 2026
Lukasz Szarpak, Michal Pruc, Dorota Jablonska-Moczulo et al.
Background/Objectives: Treatment-resistant depression (TRD) is heterogeneous and recurrent. Psilocybin administered with structured psychological support can reduce symptoms rapidly. Support protocols differ in content and intensity, and trial design complicates estimates of the specific drug effect and durability. We reviewed efficacy, durability, mechanisms, safety, and clinical delivery in...
Frontiers in Pharmacology
October 16, 2026
Qingmei Li, Shuming Liu, Huiling Chen et al.
Objective The molecular mechanisms driving esketamine (ESK) efficacy in the pain-depression dyad (PDD) remain incompletely understood. This study investigated the effects of a sub-anesthetic ESK regimen on cortical expression profiles and exploratory signaling markers within the anterior cingulate cortex (ACC). Methods Male Sprague-Dawley rats were randomized into Sham, PDD, and PDD + ESK...
Frontiers in Psychiatry
October 16, 2026
Gilberto Sousa Alves, Humberto M. M. Dos Santos, Samira D Damasceno et al.
Background Esketamine is a promising therapeutic option for treatment-resistant depression (TRD). Intravenous (IV) administration is the most extensively studied parenteral route. However, subcutaneous (SC) administration may offer simpler, more scalable delivery. Multicenter real-world evidence comparing IV and SC routes of administration remains limited. Objective To report clinical outcomes...
Actas Españolas de Psiquiatría
October 15, 2026
Huajun Yao, Caihong Peng, Min Wu
Background:To assess whether integrating mindfulness-based stress reduction (MBSR) into refined perioperative nursing is associated with improvements in postoperative sleep disturbances, anxiety, and depression in patients undergoing coronary artery bypass grafting (CABG). Methods: We retrospectively reviewed 146 CABG patients treated at Ruijin Hospital, Shanghai Jiao Tong University School of...
medRxiv
October 15, 2026
Chlöé Müh, Pauline Favre, Isabel Karen Lütkenherm et al.
preprint
Abstract Negative emotional bias, including reduced processing of positive information and negative interpretation of ambiguous stimuli, is a core feature of depression. Esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist with rapid antidepressant effects in treatment-resistant depression (TRD), reduces depressive symptoms, but its effects on distinct components of emotional...
Epigenetics
October 15, 2026
Arghavan Nepton, Sonya C. Faber, Zachary A. Kaminsky et al.
Ketamine produces rapid antidepressant effects, but the molecular processes associated with their persistence remain poorly defined in humans. We examined longitudinal DNA methylation changes in 10 adults with major depressive disorder undergoing ketamine-assisted psychotherapy using two pre-treatment assessments (T1, T2) and one post-treatment assessment (T3). Participants received three...
Frontiers in Psychology
October 14, 2026
Georgi Panov, Presiyana Panova
Both quantum mechanics and cognitive neuroscience challenge the classical view of a passively perceived reality. Instead, they suggest that reality arises through a process of selection and stabilization from a field of possibilities. This article proposes that this “reality stabilization” framework can unify our understanding of psychosis and post-psychotic depression—two conditions that are...
Preprints.org
October 14, 2026
Domenico de Berardis, Tommaso Barlattani, Alessandro Carano et al.
preprint
Intranasal esketamine has been available for treatment-resistant depression (TRD) since 2019, but the trials that led to its approval answer only some of the questions prescribers face. About 97% of trial participants had failed only one or two antidepressant classes, and patients with bipolar disorder, psychosis, obsessive–compulsive disorder, four personality disorders, moderate-to-severe...